Critical reappraisal of remdesivir investigational trials in COVID-19. (November 2020)

• Record Type: Journal Article
• Authors: Brouqui, P.; Giraud-Gatineau, A.; Raoult, D.
• Is Part Of: New microbes and new infections. Volume 38(2020)
• Publication Date: 2020-11
• Subjects: Clinical trials -- COVID-19 -- remdesivir -- treatment; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; Microbiology -- Periodicals; Communicable Diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1016/j.nmni.2020.100745
• Languages: English
• ISSNs: 2052-2975

Abstract

Abstract: During disease outbreaks, the pharmaceutical industry generally puts a lot of effort into promoting clinical trials studying their new drugs. We review evidence of the ten most recent reports on remdesivir. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention during the COVID-19 pandemic.